Ewenstein; Bruce

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ewenstein; Bruce.The latest application filed is for "treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf".

Company Profile

7.5.10

Ewenstein; Bruce - Brookline MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment Of Patients With Severe Von Willebrand Disease Undergoing Elective Surgery By Administration Of Recombinant Vwf App 20220168397 - Chapman; Miranda ; et al.	2022-06-02
Use Of Adamts13 For Treating, Ameliorating And/or Preventing Vaso-occlusive Crisis In Sickle Cell Disease, Acute Lung Injury And/or Acute Respiratory Distress Syndrome App 20220047688 - EWENSTEIN; Bruce ; et al.	2022-02-17
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome Grant 11,191,818 - Ewenstein , et al. December 7, 2	2021-12-07
Treatment Of Gastrointestinal Bleeding In Patients With Severe Von Willebrand Disease By Administration Of Recombinant Vwf App 20210169989 - Chapman; Miranda ; et al.	2021-06-10
Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF Grant 10,905,746 - Chapman , et al. February 2, 2	2021-02-02
METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF) App 20200261546 - Mellgard; Bjorn ; et al.	2020-08-20
Treatment Of Gastrointestinal Bleeding In Patients With Severe Von Willebrand Disease By Administration Of Recombinant Vwf App 20200206318 - Chapman; Miranda ; et al.	2020-07-02
Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF Grant 10,632,176 - Chapman , et al.	2020-04-28
Use Of Adamts13 For Treating, Ameliorating And/or Preventing Vaso-occlusive Crisis In Sickle Cell Disease, Acute Lung Injury And App 20190336588 - EWENSTEIN; Bruce ; et al.	2019-11-07
Treatment Of Patients With Severe Von Willebrand Disease Undergoing Elective Surgery By Administration Of Recombinant Vwf App 20190091298 - Chapman; Miranda ; et al.	2019-03-28
Treatment Of Gastrointestinal Bleeding In Patients With Severe Von Willebrand Disease By Administration Of Recombinant Vwf App 20190091299 - Chapman; Miranda ; et al.	2019-03-28
Treatment Of Coagulation Disease By Administration Of Recombinant Vwf App 20160184403 - Scheiflinger; Friedrich ; et al.	2016-06-30
Treatment of coagulation disease by administration of recombinant VWF Grant 9,272,021 - Scheiflinger , et al. March 1, 2	2016-03-01
Treatment Of Coagulation Disease By Administration Of Recombinant Vwf App 20120316116 - Scheiflinger; Friedrich ; et al.	2012-12-13

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.